Hepatitis C Pricing and Reimbursement.
12 January 2015
Since the launch of Sovaldi in the US at the price of $1,000 per pill, the pricing and reimbursement of hepatitis C therapies has been in the spotlight. Although Sovaldi’s and Havoni’s clinical effectiveness are undisputed, their high prices have created barriers with regards to their uptake.
Our new Hepatitis C Pricing and Reimbursement report looks through the market context, as well as delving into the US, Japan and five major EU markets pricing and reimbursement decisions with regards to hepatitis C therapies.
How will our Hepatitis C Pricing and Reimbursement report benefit you?
- Avoid current market issues
Identify key criticisms of Sovaldi and all-oral regimens in the hepatitis C market with regards to their pricing
- Understand your market restrictions
Recognise the factors influencing a slower uptake of new hepatitis C regimens, such as Sovaldi, in European markets compared to that of the US market
- Increase your customer understanding
Understand the effect greater pressure on pricing will have on payers’ and physicians’ prioritization of hepatitis C patients.
Key questions answered
- What can current all-oral treatments do to fend off future competition?
- What options do US payers have to minimize the impact on their budgets of treating warehoused patients?
- How has Sovaldi fared in different health technology assessments and what does this mean for other hepatitis C regimens?